Clinical Trials

Neuroendocrinologic Tumors

Recruitment stopped
Ongoing Recruitment

AveNEC [Rekrutierung nach Rücksprache]

Title:A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first line chemotherapy (AveNEC)
Indication:Patients with advanced neuroendocrine carcinomas NEC G3 (WHO 2010) (excluding SCLC and Merkel cell carcinomas) who experienced tumor progression within 9 months after prior chemotherapy
Type of study:Phase II
Contact: Julia Weck (Study Nurse)
[julia.weck@med.uni-heidelberg.de]
Investigator: Dr. med. Leonidas Apostolidis (Leiter klinische Prüfung)
Trial Register: No trial registry number given.
EudraCT: 2016-004373-40 (siehe EU klinisches Studienregister)

NCT-PMO-1603 TOP-ART

Title:A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Indication:Krebs mit DNA-Reparatur-Defizite
Type of study:Phase II
Contact: Barbara Stöhr (Study Nurse)
[barbara.stoehr@nct-heidelberg.de]
Investigator: Prof. Dr. Stefan Fröhling (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03127215
EudraCT: 2017-001755-31 (siehe EU klinisches Studienregister)

STARTRK-2/ RXDX-101-92

Title:AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGEMENTS
Indication:Lokal fortgeschrittene oder metastatische solide Tumore
Type of study:Phase II
Contact: Stefanie Hofmann (Study Nurse)
[stefanie.hofmann@med.uni-heidelberg.de]
Investigator: Prof. Dr. Christoph Springfeld (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2015-003385-84 (siehe EU klinisches Studienregister)